WesternU Dean to Publish Alzheimer's Research
APR 17, 2012 - 12:46 ET
FOR: WESTERN UNIVERSITY OF HEALTH SCIENCES
POMONA, CA--(Marketwire - April 17, 2012) - Michel Baudry, PhD, dean of the Graduate College of Biomedical Sciences at Western University of Health Sciences, will publish his research on the critical role of oxidative stress in Alzheimer's disease and a potential treatment.
The article, co-authored by College of Osteopathic Medicine of the Pacific Associate Professor Xiaoning Bi, MD, PhD, will be published in the May 2012 issue of the Journal of Alzheimer's Disease.
Oxygen free radicals are ubiquitous because they are a consequence of the way we live -- in an oxygenated environment, Baudry said. We take in oxygen to burn food in order to produce energy, which is used by cells. But in the process we leak oxygen free radicals. Cells have developed a strong defense mechanism to prevent the accumulation of these reactive oxygen species because they produce a chain reaction. If the radicals are not eliminated, they damage proteins, lipids and DNA, further increasing their production by damaging mitochondria.
The brain is very susceptible to excessive formation of reactive oxygen species. Alzheimer's disease may create a vicious cycle with the amyloid beta peptide, a peptide presumably involved in the disease, impairing mitochondrial function, resulting in the creation of these reactive oxygen species, which then results in further cell damage.
Baudry, in collaboration with Dr. Bernard Malfroy, now CEO of MindSet Rx, Inc., discovered a series of manganese complexes, EUKn, that act like enzymes to fight reactive oxygen species. EUKn cannot be swallowed in pill form because they get destroyed in the stomach, so they must be injected.
The goal of the study was to examine whether reactive oxygen species are critically involved in Alzheimer's disease and to test the effectiveness of one of the EUKn, EUK-207, in protecting against symptoms of the disease and progression of these symptoms.
Mice modeling human Alzheimer's disease (AD) were treated with EUK-207 for five months starting at four months before the appearance of AD symptoms. The non-treated mice had increased oxidative stress and AD symptoms. The treated mice had none of these markers of oxidative stress, and were protected from most of the pathology associated with Alzheimer's disease, Baudry said.
"This suggests the increased formation of reactive oxygen species is causally related to the disease," he said. "If you block oxidative stress, you block the appearance of the disease."
In the second part of the study, mice were treated with EUK-207 for three months starting at nine months of age, when AD symptoms were clearly present.
"We found the treatment prevented further accumulation of oxidative stress, and significantly reduced the further progression of the pathology," Baudry said.
The study was supported by the Alzheimer's Association. Baudry and Dr. Malfroy are now exploring the possibility of putting EUK-207 in a clinical trial in collaboration with an undisclosed partner.
The article is slated for publication in the Journal of Alzheimer's Disease, 30:1, which is scheduled for online publication ahead of print on May 8, 2012. An early online version: http://iospress.metapress.com/content/p4q668360856x546/?p=03f8df0dbef048e4b7a2f6f60ac6b964&pi=1
NOTES FOR EDITORS